Table 3.
Association analysis results (p < 1x 10−7) for variants with MAF ≥ 5 %
| Pheno | TNFi | Gene region | SNP | Chr | BP | A1 | A2 | Genotype counts | MAF | P | Beta | SE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SJC28 | Infliximab | intronic FTO | rs7195994 | 16 | 54060205 | G | A | 363/68/3 | 0.085 | 9.74E-09 | −0.48 | 0.08 |
| SJC28 | Adalimumab | intergenic BRINP1/LINC01613 | rs10739537 | 9 | 122188604 | G | T | 70/275/206 | 0.377 | 9.11E-08 | −0.21 | 0.04 |
| PGA | Etanercept | intergenic MMP20/MMP27 | rs948138 | 11 | 102501665 | G | A | 132/292/191 | 0.452 | 7.62E-08 | 0.25 | 0.05 |
| TJC28 | Infliximab | intergenic C10orf90/DOCK1 | rs11599217 | 10 | 128566964 | G | T | 128/210/96 | 0.463 | 7.27E-08 | −0.29 | 0.05 |
| TJC28 | All | intronic ZNF595,ZNF718 | rs2187874 | 4 | 82321 | G | T | 1279/397/47 | 0.142 | 7.00E-08 | −0.19 | 0.04 |